Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Achillion gets $225mm equity investment from JJDC

Executive Summary

Johnson & Johnson Development Corp. made a $225mm equity investment in Achillion Pharmaceuticals Inc., buying about 18.4mm new unregistered shares at $12.25 each (a 28% premium). Concurrently, Achillion licensed Janssen Pharmaceuticals Inc. exclusive worldwide rights to develop and commercialize hepatitis C assets including ACH3102, ACH3422, and sovaprevir.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies